Nova Scotia Becomes Sixth Jurisdiction To Implement Biosimilar Switching

Policy Welcomed By Trade And Advocacy Groups

Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis. 

Nova Scotia flag
Seven biosimilars have been included in the initial policy • Source: Alamy

Nova Scotia has become the sixth Canadian jurisdiction and fifth province to implement a biosimilar switching policy in its public health program, a move which is expected to save the local government an estimated CAD13m ($10.2m) annually.

The Nova Scotia announcement follows the implementation of similar policies in British Columbia, Alberta, New Brunswick and Quebec. A fifth...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.